SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on February 6, 2003; DOI 10.1182/blood-2002-06-1925. This Article Full Text (PDF) All Versions of this Article: 2002-06-1925v1 101/11/4607    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Rasmussen, T. Articles by Mellstedt, H. Search for Related Content PubMed PubMed Citation Articles by Rasmussen, T. Articles by Mellstedt, H. Social Bookmarking                   What's this? Submitted July 11, 2002 Accepted January 23, 2003 Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells Thomas Rasmussen, Lotta Hansson, Anders Osterborg, Hans Erik Johnsen, and Hakan Mellstedt* Herlev Hospital, University of Copenhagen, Herlev, Denmark Department of Oncology (Radiumhemmet) and Hematology, Karolinska Hospital, Stockholm, Sweden * Corresponding author; email: hakan.mellstedt{at}ks.se. Myeloma cells express the idiotype (Id)-specific antigen that may be targeted by idiotype vaccination. Six stage I IgG myeloma patients were immunized with the autologous purified M-component together with the ajuvant cytokines IL-12 alone or in combination with GM-CSF. The effect of Id vaccination on circulating clonal tumor B cells was monitored by a real-time allele-specific oligonucleotides PCR method. No other treatment was given. Blood tumor mass reduction was observed in 4/6 patients, with one patient achieving a complete molecular remission in blood. In 3 of these 4 patients an idiotype specific T cell response was induced. In the remaining two patients with an unchanged level of blood tumor cells, one patient mounted a T cell response while the other did not. No significant change in the serum M-comp. conc. was noted. Id vaccination may target clonal B cells suggesting that this strategy might be complementary to achieve tumor control. The clinical significance of these findings remains to be established. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: C. A. Huff and W. Matsui Multiple Myeloma Cancer Stem Cells J. Clin. Oncol., June 10, 2008; 26(17): 2895 - 2900. [Abstract] [Full Text] [PDF] A. O. Abdalla, P. Kokhaei, L. Hansson, H. Mellstedt, and A. Osterborg Idiotype vaccination in patients with myeloma reduced circulating myeloma cells (CMC) Ann. Onc., June 1, 2008; 19(6): 1172 - 1179. [Abstract] [Full Text] [PDF] A. C. Rawstron, A. Orfao, M. Beksac, L. Bezdickova, R. A. Brooimans, H. Bumbea, K. Dalva, G. Fuhler, J. Gratama, D. Hose, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders Haematologica, March 1, 2008; 93(3): 431 - 438. [Abstract] [Full Text] [PDF] L. Hansson, A. O. Abdalla, A. Moshfegh, A. Choudhury, H. Rabbani, B. Nilsson, A. Osterborg, and H. Mellstedt Long-term Idiotype Vaccination Combined with Interleukin-12 (IL-12), or IL-12 and Granulocyte Macrophage Colony-Stimulating Factor, in Early-Stage Multiple Myeloma Patients Clin. Cancer Res., March 1, 2007; 13(5): 1503 - 1510. [Abstract] [Full Text] [PDF] T. Azuma, T. Otsuki, K. Kuzushima, C. J. Froelich, S. Fujita, and M. Yasukawa Myeloma Cells Are Highly Sensitive to the Granule Exocytosis Pathway Mediated by WT1-Specific Cytotoxic T Lymphocytes Clin. Cancer Res., November 1, 2004; 10(21): 7402 - 7412. [Abstract] [Full Text] [PDF] S.A. Schey, P. Fields, J.B. Bartlett, I.A. Clarke, G. Ashan, R.D. Knight, M. Streetly, and A.G. Dalgleish Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma J. Clin. Oncol., August 15, 2004; 22(16): 3269 - 3276. [Abstract] [Full Text] [PDF] M. Y. Mapara and M. Sykes Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance J. Clin. Oncol., March 15, 2004; 22(6): 1136 - 1151. [Abstract] [Full Text] [PDF] M. Grube, K. Rezvani, A. Wiestner, H. Fujiwara, G. Sconocchia, J. J. Melenhorst, N. Hensel, G. E. Marti, L. W. Kwak, W. Wilson, et al. Autoreactive, Cytotoxic T Lymphocytes Specific for Peptides Derived from Normal B-Cell Differentiation Antigens in Healthy Individuals and Patients with B-Cell Malignancies Clin. Cancer Res., February 1, 2004; 10(3): 1047 - 1056. [Abstract] [Full Text] [PDF] M. A. Caligiuri, A. Velardi, D. A. Scheinberg, and I. M. Borrello Immunotherapeutic Approaches for Hematologic Malignancies Hematology, January 1, 2004; 2004(1): 337 - 353. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020